DaVita AI Stock Analysis
DaVita (TRL) AI Stock Analysis
DaVita
(BX Swiss:TRL)
No summary available
DaVita Business Overview & Revenue Model
Company Description
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, suppleme...
DaVita Earnings Call Summary
The call was predominantly positive, with solid third-quarter results, improved clinical outcomes, strong expanded HD adoption and rollout readiness, significant IKC earnings growth, continued international improvement and maintained full-year free cash flow expectations. These positives were tempered by higher technology spending, below-historical treatment volume growth, missed-treatment pressure, commercial-mix and ACA headwinds, higher operating costs and uncertainty around future ESRD reimbursement adjustments and policy economics.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For full year 2026, DaVita now expects adjusted operating income within a range of $2.175 billion to $2.25 billion, adjusted earnings per share within a range of $14.30 to $15.20, free cash flow between $1 billion and $1.25 billion, IKC adjusted operating income of at least $65 million, and approximately $135 million of international adjusted operating income; the company expects a $40 million year-over-year headwind from ACA exchanges, an approximately 1% headwind to fourth-quarter treatment volume from year-over-year day mix, and treatments per normalized day up more than 1% in Q4, while 2027 volume growth is expected to be higher than volume growth in 2026, pharmaceutical costs are expected to come down, and IT spend is expected to decelerate from 20-plus percent growth but continue to grow. Expanded HD is expected to have no material net impact on adjusted operating income for 2026 or 2027, with the positive impact of lower mortality and higher volume growth beginning in the back half of 2028 and supporting a path back to 2% or greater volume growth by 2029. For full year '27, the estimated net impact of the ESRD final rule is 1.5% to 2%, with 1% worth about $30 million a year, while the 40 basis points excluding TDAPA is fixed for the year and the 3.1% TDAPA component applies only to Q1 and is expected to come down significantly in Q2 and stay down and potentially further decline over the course of the year.
DaVita Risk Analysis
DaVita disclosed 26 risk factors in its most recent earnings report. DaVita reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksDaVita Peers Comparison
Overall Rating
THC87Outperform
ENSG75Outperform
EHC70Outperform
FMS66Neutral
HCA64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 87Outperform | $22.76B | 8.24 | 60.60% | ― | 6.23% | 136.09% | |
| 75Outperform | $10.99B | 27.27 | 16.63% | 0.14% | 17.49% | 19.82% | |
| 70Outperform | $13.83B | 21.76 | 25.17% | 0.55% | 9.36% | 20.78% | |
| 66Neutral | $11.75B | 13.41 | 6.34% | 3.92% | 4.27% | 26.14% | |
| 64Neutral | $104.25B | 16.49 | -100.45% | 0.61% | 5.82% | 16.59% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FMS | Fresenius Medical Care | 22.03 | -0.36 | -1.63% | |
| HCA | Hca Healthcare | 499.05 | 25.19 | 5.32% | |
| EHC | Encompass Health | 140.99 | 29.81 | 26.82% | |
| THC | Tenet Healthcare Corp. | 286.03 | 93.63 | 48.66% | |
| ENSG | The Ensign | 188.41 | 11.11 | 6.27% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
